About Us

Philosophy

To contribute towards the well-being and improving the health of people around the globe through the provision of innovative and reliable pharmaceutical products and services.

Mission

To be a globally admired, innovative, well recognized, best-in-class pharmaceutical company thereby enhancing the enterprise value in a sustainable manner with top quality management.

To dedicate to humanity’s quest for longer, healthier, happier lives through innovation in medicines.

To serve Global Healthcare needs through Empathy, Innovation, and Technology.

To gain the trust of all stakeholders to enhance the enterprise value and long-lasting business relationships.

Vision

To become globally recognized as an integrated pharmaceutical company through Innovation, Quality and Competence.

To become a leading pharmaceutical player in the industry by assuring high quality standards and cost effective products at all times. We want to mark our presence in the society by creating a portfolio of low cost medicines available to all.

Progressive Path

2018

Establishment of R&D facility (1000 Sq. ft)
3+ Generic Products targeted for US/EU

2020

New R&D set up (5000+ Sq. Ft.)
Diverse dosage form portfolio expansion
Client Audit completion for one generic
Two Provisional patents filed
Presence in USA

2022

Facility expansion with in-house 505(b)(2) and niche Generics portfolio
LFDA and CDSCO facility approval
USA operation expansion (8000+ Sq. Ft.)
Receipt of Duns #
CC initiated with USFDA for ANDA
Gateway for Pre-IND received
FEI # received for labelling and packaging
Successful audit by NJ Health
First 505(b)(2)/NDA out-licensed to US-based large pharma

2023 Q1

Established virtual model for product development and filing with USFDA
Seven ANDA products' CC received from USFDA
Five 505(b)(2) products in development
Four patents filed for 505(b)(2) products
Exhibit batches planned with USFDA approved CDMO

Leadership Team

Our leadership team has got diverse experience of Drug Discovery from 'end-to-end'. Our CEO has a proven track record of more than two decades of experience in pharmaceuticals industry. His experience spans across injectables end-to-end product development and manufacturing landscape ranging from liquid, suspension, lyophilised, cytotoxin, non-cytotoxin, protein & peptide, complex oral dosage forms and ophthalmic formulations focused for US Market.

Our CSO brings extensive experience of drug discovery from 'bench to bedside'. This includes early stage drug discovery including medicinal chemistry, pre-clinical biolology, IND-enabling studies and submission. He has worked with multiple collaborators globally on diverse therapeutic area across various stages of discovery.